GSK is pushing its flu vaccine candidate into a crucial late-stage trial. The company plans to start a Phase III trial in September 2026. The move follows positive Phase II results for its mRNA flu vaccine candidate. The vaccine produced stronger...
Low-dose GLP-1 drugs can still help people lose weight, even when patients remain on the starter dose. However, the weight loss is much lower than results seen with higher doses.
Manipur Chief Minister Yumnam Khemchand Singh meets Union Health and Family Welfare Minister JP Nadda in New Delhi. During the discussion, Nadda agrees to upgrade the Regional Institute of Medical Sciences in Imphal to AIIMS
ICMR researchers reveal a clear mortality risk linked to drug-resistant infections in a major new study. The findings show these infections raise death rates, treatment costs, and hospital stays across Indian tertiary hospitals
The push to lower drug prices in America has gained momentum as Sun Pharma joins eight pharmaceutical companies in a new US pricing deal.
Autoimmune therapies, oncology advances, and major takeovers take center stage as three significant biologics deals reshape industry pipelines today
This month brought several developments that shaped India's pharma industry, from new partnerships and licensing agreements to R&D expansion and international market opportunities
Zydus Lifesciences just moved the needle in the global fight against liver disease. The company's EVIDENCES-X Phase II trial for Saroglitazar Mg met its primary endpoint, with 26.5 percent treatment difference over placebo to resolve steatohepatitis
Aurobindo Pharma has marked a major milestone as its US subsidiary, Lannett Company LLC, launched the generic version of Advair Diskus in the American market on 31 August 2026
India-Brazil Trade is set for a major expansion as both countries target USD 30 billion in bilateral trade by 2030. The India-Brazil Trade partnership is also gaining momentum through wider market access for Indian pharmaceutical products.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")